ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Atlanta, GA, USA:

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp
Drug: Tebentafusp with Pembrolizumab

Phase 2, Phase 3

Immunocore
Immunocore

Atlanta, Georgia, United States and 70 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Atlanta, Georgia, United States and 49 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Atlanta, Georgia, United States and 55 other locations

immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ...

Active, not recruiting
Cutaneous Melanoma, Stage III
Stage IIIA Skin Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Emory University
Emory University

Atlanta, Georgia, United States

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Atlanta, Georgia, United States and 65 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 171 other locations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Enrolling
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 36 other locations

and/or nivolumab work in treating participants with stage IIIB-D melanoma that can be removed by surgery. Monoclonal antibodies, such as VX1...

Active, not recruiting
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Biological: Ipilimumab
Biological: VX15/2503

Phase 1

Emory University
Emory University

Atlanta, Georgia, United States

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 128 other locations

manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant thera...

Enrolling
Melanoma Stage IIIB/C
Procedure: Surgery
Drug: Daromun

Phase 3

Philogen
Philogen

Atlanta, Georgia, United States and 33 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems